




## AMSELAMINE, A NEW SELECTIVE HISTAMINE H<sub>2</sub>-RECEPTOR AGONIST<sup>#</sup>

Henk van der Goot\*, John Ch. Eriks, Rob Leurs and Hendrik Timmerman  
*Leiden/Amsterdam Center for Drug Research*  
*Department of Pharmacocochemistry, Free University, De Boelelaan 1083,*  
*NL-1081 HV Amsterdam, The Netherlands*


**Abstract.** The synthesis of amselamine (2-amino-5-(2-aminoethyl)-4-methyl-1,3-selenazole), a potent histamine H<sub>2</sub>-agonist, has been described. At the guinea pig right atrium amselamine revealed to be slightly more active than its sulfur analogue amthamine and histamine. Moreover negligible effects on H<sub>1</sub> and H<sub>3</sub>-receptors were observed.

### Introduction

During long time the possibility of a tautomeric shift of the ligand, as can be very easily achieved in the imidazole structure of histamine (1), has been thought to be a structural requirement for the stimulation of the histamine H<sub>2</sub>-receptor<sup>1</sup>. Although several authors questioned the necessity of a tautomeric shift<sup>2</sup>, recently Eriks et al.<sup>3</sup> provided evidence that also non-tautomeric structures can be H<sub>2</sub>-agonists. Examples are found in a series of thiazoles, with amthamine (2a) being the most active compound of the series.



1. histamine



2a. amthamine (X = S)  
 2b. amselamine (X = Se)


Since it has been shown that in these type of compounds the pK<sub>a</sub> of the heterocyclic system is determining the affinity to the H<sub>2</sub>-receptor, it is interesting to vary X in structure 2 in order to modify the pK<sub>a</sub> of the ring system. Preliminary calculations revealed that the selenazole 2b might be expected to possess fairly high histamine H<sub>2</sub>-agonistic activity. Therefore this compound was prepared and pharmacologically evaluated.

### Chemistry

The selenazole 2b was prepared as indicated in scheme 1. The phthalimidobromopentanone<sup>4</sup> 3 was condensed with selenourea (4) in refluxing ethanol during 6 hrs. After cooling 2-amino-4-methyl-5-[2-(N-phthalimido)ethyl]-1,3-selenazole (5) was filtered off as the hydrobromide and crystallized from ethanol. Yield 95%, melting point 206.2 - 208.9°C.

<sup>#</sup> To the memory of John Eriks who died October 26<sup>th</sup>, 1992.

Scheme 1



$^1\text{H-NMR}$  (200 MHz) in  $d_6$ -DMSO: 1.90 ppm (singlet,  $\text{CH}_3$ ), 2.94 ppm (triplet,  $J = 6.1$  Hz,  $\text{ArCH}_2$ ), 3.96 ppm (triplet,  $J = 6.1$  Hz,  $\text{NCH}_2$ ), 7.88 ppm (singlet,  $4 \times \text{ArH}$ ), 9.36 ppm (broad singlet,  $\text{NH}_2$ ), 12.52 ppm (broad singlet,  $^+\text{NH}$ ).

Subsequently the phthalimidoselenazole 5 was hydrolyzed in refluxing 48% HBr during 5 hrs. After evaporation to dryness the residue (2b) was crystallized three times from ethanol. Yield 56%, melting point  $249.6 - 250.0^\circ\text{C}$ .

$^1\text{H-NMR}$  (200 MHz) in  $d_6$ -DMSO: 2.11 ppm (singlet,  $\text{CH}_3$ ), 2.99 ppm (singlet,  $2 \times \text{CH}_2$ ), 8.00 ppm (broad singlet,  $^+\text{NH}_3$ ), 9.39 ppm (broad singlet,  $\text{NH}_2$ ), 12.65 (broad singlet,  $^+\text{NH}$ ).

Mass spectrum (EI, 70 eV): found:  $m/e = 205.0129$ , calculated for  $\text{C}_6\text{H}_{11}\text{N}_3^{80}\text{Se}$ : 205.0118.


Titration with 0.1 N NaOH in water containing 0.162 M  $\text{KNO}_3$  revealed that the equivalent weight of the sample prepared was 99.8% of the theoretical value. The  $\text{pK}_a$  values calculated from the titration curve are indicated in table 1. Results of elemental analysis were within 0.4 % of the theoretical value for C, H and N.

### Pharmacology

Histamine  $\text{H}_2$ -activity was determined on the isolated spontaneously beating guinea pig right atrium according to Sterk *et al.*<sup>5</sup> The  $\text{pD}_2$  values were derived from the 50% level of the maximum response of the agonistic dose-response curves. Affinity to the  $\text{H}_2$ -receptor was determined on rat histamine  $\text{H}_2$ -receptors expressed in CHO cell as described by Traiffort *et al.*<sup>6</sup> using [ $^{125}\text{I}$ ]-iodoaminopotentidine as the radioligand; the displacement curves were analysed with the program LIGAND<sup>7</sup>.

Amselamine (2b) behaves as a full agonist with a  $\text{pD}_2$  value of 6.41 which makes it slightly more potent than histamine and amthamine (2a). Its  $\text{H}_2$ -agonistic character was verified with cimetidine as antagonist. Cimetidine appeared to be a competitive antagonist with a  $\text{pA}_2$  value of  $6.41 \pm 0.04$  (3) with amselamine as agonist, which is in accordance with reported values using other agonists<sup>2</sup>. Dose-response curves are shown in fig. 1.


Table 1 Pharmacological data and basicity of H<sub>2</sub>-agonists.

				
X	pD <sub>2</sub> ± s.e.m. <sup>a</sup>	pK <sub>d</sub> ± s.e.m. <sup>b</sup>	pK <sub>a1</sub> ± s.e.m. <sup>c</sup>	pK <sub>a2</sub> ± s.e.m. <sup>d</sup>
2b Se	6.41 ± 0.08 (6)	5.01 ± 0.02 (3)	9.21 ± 0.01 (4)	5.78 ± 0.01 (4)
2a S	6.21 ± 0.09 (7)	4.94 ± 0.06 (3)	9.15 ± 0.02 (6)	5.40 ± 0.01 (6)
histamine	6.14 ± 0.04 (22)	3.93 ± 0.06 (3)	9.32 ± 0.14 (3)	5.93 ± 0.14 (3)

a. Guinea pig right atrium; b. CHO rat H<sub>2</sub> cells; c. aliphatic amine; d. heterocyclic ring.

Amselamine shows very weak interactions with histamine H<sub>1</sub>- and H<sub>3</sub>-receptors. Thus concerning H<sub>1</sub>-activity (guinea pig ileum) a pA<sub>2</sub>-value of 3.85 ± 0.07 (4) against histamine was found, whereas in the test for H<sub>3</sub>-activity (electrically stimulated guinea pig jejunum)<sup>8</sup> a pD<sub>2</sub>-value of 4.44 ± 0.05 (3) was established. These results make amselamine a selective and relatively potent histamine H<sub>2</sub>-agonist.

Fig. 1 Functional effects of amselamine on histamine H<sub>2</sub>-receptors.  
(Guinea pig right atrium, chronotropic effect)




#### Interaction with the H<sub>2</sub>-receptor

Recently we provided evidence<sup>3</sup> that monocations of histamine, dimaprit and a number of thiazoles exert their interaction with the histamine H<sub>2</sub>-receptor through H-bond formation with the primary ammonium group, protonation of the aromatic N-atom and H-bond formation (if X = NH) or electrostatic interaction (if X = S) as

shown in fig. 2.

Fig. 2 Binding to the histamine H<sub>2</sub>-receptor



Since the selenazole ring of amselamine is somewhat more basic than the thiazole ring of amthamine (table 1), it may be expected that amselamine has a slightly higher affinity for the H<sub>2</sub>-receptor than amthamine. However, since amthamine and amselamine exert almost equal affinities for the histamine H<sub>2</sub>-receptor on CHO cells, such a statistically significant higher affinity was not established.

### Conclusion

It appeared that the seleno analogue of the potent histamine H<sub>2</sub>-agonist amthamine, which is designated as amselamine, behaves as a potent histamine H<sub>2</sub>-agonist with a higher potency than histamine itself. Moreover amselamine exerts hardly any activity for histamine H<sub>1</sub>- and H<sub>3</sub>-receptors, which makes it selective for the histamine H<sub>2</sub>-receptor.

**Acknowledgement.** The research of Dr. R. Leurs has been made possible by a fellowship of the Royal Netherlands Academy of Arts and Sciences.

### References

1. Weinstein, H.; Chou, D.; Johnson, C.L.; Kang, S.; Green, J.P. *Mol. Pharmacol.* **1976**, *12*, 738.
2. Van der Goot, H.; Bast, A.; Timmerman, H. *Handbook of Experimental Pharmacology*; Uvnäs, B., Ed.; Springer-Verlag: Berlin, 1991; Vol. 97, pp. 573 - 748.
3. Eriks, J.C.; Van der Goot, H.; Timmerman, H. *Mol. Pharmacol.* **1993**, *44*, 886.
4. Eriks, J.C.; Van der Goot, H.; Sterk, G.J.; Timmerman, H. *J. Med. Chem.* **1992**, *35*, 3239.
5. Sterk, G.J.; Van der Goot, H.; Timmerman, H. *Eur. J. Med. Chem.* **1984**, *19*, 545.
6. Traiffort, E.; Ruat, M.; Arrang, J.M.; Leurs, R.; Pomelli, D.; Schwartz, J.C. *Proc. Natl. Acad. Sci.* **1992**, *89*, 2649.
7. Munson, P.J.; Rodbard, D. *Anal. Biochem.* **1980**, *107*, 220.
8. Vollinga, R.C.; Zuiderveld, O.P.; Scheerens, H.; Bast, A.; Timmerman, H. *Meth. Find. Exp. Clin. Pharmacol.* **1992**, *14*, 747.

(Received in Belgium 3 March 1994; accepted 19 May 1994)